The immune reactivity of allogeneic lymphocytes plays a major role in the control of leukemia after bone marrow transplantation. In patients with recurrent leukemia after marrow transplantation, chimerism and tolerance provide ideal conditions for adoptive immunotherapy with donor lymphocytes. We studied the effect of donor lymphocyte transfusions on acute and chronic leukemia in relapse after bone marrow transplantation. One hundred thirty-five patients with chronic myeloid leukemia (CML) (N = 84). acute myeloid leukemia (AML) (N = 23). acute lymphoblastic leukemia (ALL) (N = 221, myelodysplastic syndrome (MDS) (N = 5), and polycythemia vera with osteomyelofibrosis (PCV) (N = 1) were treated with transfusions of donor lymphocytes. Patients were monitored for response of leukemia, including in CML, the use of the polymerase chain reaction for bcrlabl mRNA transcripts and for the occurrence of graft-versushost disease (GVHD) and myelosuppression. Complete remissions were induced by donor lymphocyte transfusions HE ROLE OF ALLOGENEIC lymphocytes in the eradication of leukemia is well established. In mice, transplantation of allogeneic bone marrow eliminated leukemia, and transplantation of marrow from syngeneic donors failed.' Allogeneic marrow transplantation as a form of adoptive immunotherapy of leukemia was limited by the inevitable occurrence of graft-versus-host disease (GVHD).' Patients with GVHD had fewer relapses than patients without GVHD, but only patients with mild degrees of GVHD had a survival ad~antage.~ T lymphocytes are most probably responsible for GVHD and the graft-versus-leukemia (GVL) effect; depletion of T lymphocytes decreased the incidence and seventy of GVHD, but increased the risk of relapse.",' However, a beneficial effect of adding T lymphocytes early after transplantation on high-risk leukemia could not be shown. Transfusion of donor lymphocytes early after transplantation increased the incidence and seventy of acute GVHD without improving the control of leukemia? A possible solution of the dilemma between the risk of GVHD and the benefit of a GVL effect was sought in delaying the transfusion of donor lymphocytes to a time when GVH tolerance was established. In canine chimeras, the delay of the transfusion for 2 months or longer after transplantation prevented acute GVHD without abrogating the beneficial effect on chimerism and the transfer of immunity.' Indeed, the first patients treated with transfusion of donor lymphocytes showed only mild or no GVHD.8
HE ROLE OF ALLOGENEIC lymphocytes in the eradication of leukemia is well established. In mice, transplantation of allogeneic bone marrow eliminated leukemia, and transplantation of marrow from syngeneic donors failed.' Allogeneic marrow transplantation as a form of adoptive immunotherapy of leukemia was limited by the inevitable occurrence of graft-versus-host disease (GVHD).' Patients with GVHD had fewer relapses than patients without GVHD, but only patients with mild degrees of GVHD had a survival ad~antage.~ T lymphocytes are most probably responsible for GVHD and the graft-versus-leukemia (GVL) effect; depletion of T lymphocytes decreased the incidence and seventy of GVHD, but increased the risk of relapse.",' However, a beneficial effect of adding T lymphocytes early after transplantation on high-risk leukemia could not be shown. Transfusion of donor lymphocytes early after transplantation increased the incidence and seventy of acute GVHD without improving the control of leukemia? A possible solution of the dilemma between the risk of GVHD and the benefit of a GVL effect was sought in delaying the transfusion of donor lymphocytes to a time when GVH tolerance was established. In canine chimeras, the delay of the transfusion for 2 months or longer after transplantation prevented acute GVHD without abrogating the beneficial effect on chimerism and the transfer of immunity.' Indeed, the first patients treated with transfusion of donor lymphocytes showed only mild or no GVHD. 8 In the meantime, we8 and others9-I5 have shown that remissions can be induced in patients with chronic myelogenous leukemia (CML) in relapse after marrow transplantation by the transfusion of lymphocytes from the marrow donor without chemo or radiotherapy. Occasional patients with acute myeloid leukemia (AML) have benefited from donor lymphocyte transfusions,*6 but in general, the response of different types of leukemia to the GVL effects of donor lymphocyte transfusions is not known. Here we review the results in 54 patients with CML (73%) and in the patient with PCV; complete remissions were also induced in five patients (29%) with AML and a patient with MDS. In contrast, ALL did not respond to adoptive immunotherapy with donor lymphocyte transfusions. Remissions were durable in patients treated for CML in chronic phase (probability of remission: 87% at 3 years). Lymphocyte transfusions were also given to 18 patients with ALL, AML, MDS, and transformed phase CML who were in remission after chemotherapy. These remissions were not durable. Fifty-two patients (41%) developed GVHD of grade 2 or more, and 41 patients (34%) showed signs of myelosuppression. Seventeen patients died without leukemia, 14 patients with GVHD andlor myelosuppression. Donor lymphocyte transfusions exert strong effects against myeloid forms of leukemia and induce durable remissions in CML. reported by 27 transplant centers in the European Group for Blood and Marrow Transplantation (EBMT) and evaluate the risks and benefits of donor lymphocyte transfusions in patients with recurrent CML in various stages, AML, acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and polycythemia vera (PCV).
MATERIALS AND METHODS
Data collection. Centers for bone marrow transplantation participating in the European Group for Blood and Marrow Transplantation (EBMT) were asked to report their experience with donor lymphocyte transfusions for the treatment of recurrent leukemia after marrow transplantation. Between May 1992 and May 1994, we received reports on 140 treatment episodes in 135 patients from 27 centers. Attempts were made to prevent selective reporting of favorable cases. Centers were asked to report all sequentially treated patients, and the results were discussed with each center.
The reports included data on age and sex of the patients and their donors, diagnosis and stage of the disease at the time of transplantation, histocompatibility and relationship of the donor, date of transplant, conditioning regimen, method of prophylaxis of GVHD. severity of acute and chronic GVHD, as well as other major complications after transplantation, time of relapse, leukocyte count and the percentage of blasts, cytogenetic data on the percentage of Philadelphiapositive metaphases and other karyotqpe abnormalities, presence of GVHD and evidence of chimerism at the time of leukemic relapse, and in case of CML, the type of relapse, ie, cytogenetic, hematologic, or in transformation. Treatment related information included details of chemotherapy, the dates of administration and response. details of treatment with interferon-cu and clinical, as well as cytogenetic response, date and number of days with lymphocyte transfusions, number of mononuclear cells transfused, and the response to the transfusion. The outcome of the treatment was assessed by: (I) severity of GVHD, involvement of skin, liver and gut; (2) leukopenia, thrombocytopenia, and reticulocytopenia secondary to the lymphocyte transfusion and unrelated to chemotherapy; (3) response of the leukemia including karyotype analyses and reverse transcriptase polymerase chain reactions of bcdubl c-DNA. Survival, causes of morbidity and death, and recurrence of leukemia after lymphocyte transfusions were also evaluated.
Patienrs. The patients' characteristics are summarized in Table  I . Eighty-four patients were treated for recurrent CML, 1 patient for PCV, 23 patients for AML, 5 patients for MDS, and 22 patients for ALL. The median age of both the patients and the donors was 35 years. One hundred seventeen patients had an HLA-identical sibling donor, 11 patients had an unrelated donor, in 6 patients the donor was mismatched for one HLA-antigen, and I patient had a monorygotic twin donor.
Definitions. Relapse of leukemia was detined as the recurrence of signs and symptoms of leukemia including cytogenetic evidence. In CML, cytogenetic relapse was defined as the recurrence of metaphases with the Philadelphia-chromosome without hematologic or clinical features of CML. Hematologic relapse is the recurrence of CML with the characteristics of chronic phase disease, whereas transformed relapse is the recurrence with the characteristics of accelerated or blastic phase. Blastic phase is detined as an inclease of blasts in marrow to 30% or more and/or in blood to 20% or more. Accelerated phase is defined as an incwase of blasts, eosinophils, and basophils unresponsive to conventional chemotherapy not fultilling the criteria of blast phase.
In PCV. relapse was defined as recurrence of host hematopoiesis with leukocytosis and thrombocytosis.
Conlplete remission was defined as the absence of signs or symptoms of leukemia and the return of normal blood counts and bone marrow cellularity in the absence of antileukemic therapy. In CML, a negative reverse transcriptase polymerase chain reaction (KT-PCR) for bcr/ubl transcripts" in marrow or blood and/or the absence of metaphases with the Philadelphia chromosome was necesaary for confirmation. Initially only cytogenetic results were available: until more recent RT-PCR was established as a standard method. Response was evaluable in patients who survived at least 30 days after lymphocyte transfusions because the earliest responses were observed 4 weeks after treatment.
Leukocytopenia and thrombocytopenia unrelated to chemotherapy did not contradict the definition of complete remission based on RT-PCR and cytogenetic results, because they may occur in the course of a GVL reaction.
Cytopenia caused by marrow aplasia was observed in some patients l or 2 months after lymphocyte transfusion. Myelosuppression was defined as a hypocellular marrow with the decrease of leukocyte counts below 1.0 g L and/or platelet counts below 20 g/L and/or reticulocyte counts below 0.2%.
GVHD was staged clinically according to the criteria described by Glucksberg et Lymnphocyrr rransfusions. Lymphocyte concentrates were collected from the donor as buffy coat preparations enriched in mononuclear cells using cell separators. Collections were performed on one or more occasions within 1 or 2 weeks. Between 0.1 and 15 X IOx mononuclear cells were transfused per kilogram of body weight (Table I) . Nine patients were given infusions of increasing numbers of cells over several weeks. Four patients with CML and one patient with ALL received several courses of treatment.
In these patients only the first course was evaluated.
Sturisricul unulysis. The response data were initially analyzed by two-by-k chi-square contingency analysis with k equal to the nurnber of groups. If P values were 5 2 , the variables were evaluated in a stepwise logistic regression analysis.
Survival time and duration of remissions were evaluated by Kaplan-Meier curves and comparisons between these groups were made by log-rank tests. P values < .05 were considered statistically significant.
RESULTS
Response to donor lymphocyte transfusions. Complete hematologic and cytogenetic remission was achieved in S4 of 75 evaluable patients with CML and in the patient with PCV. In CML, remissions were confirmed by the absence of bcrlabl-RNA transcripts in 42 of the 44 patients studied using PCR analysis. Complete remissions were induced in 5 of 17 patients with AML and in 1 of 4 patients with MDS who had either not responded or who had not received intensive chemotherapy before donor lymphocyte transfusions. However, no remissions were induced in 12 patients with ALL who had failed to respond to intensive chemotherapy or in patients who received donor lymphocyte transfusions as sole therapy (Table 2) . Donor lymphocytes were transfused for consolidation of chemotherapy-induced remission in 9 patients with ALL, 4 patients with AML, a patient with MDS, and 4 patients with CML in transformed phase (Table 3) . Donor lymphocyte transfusions failed to sustain remissions in 6 of 9 patients with ALL, 2 of 4 patients with AML, and 2 of 4 patients with CML in transformed phase.
Remissions were durable in patients treated in cytogenetic and hematologic relapse of CML and in the patient with PCV. Only 3 of 54 patients treated in chronic phase and 3 of S patients treated in transformed phase relapsed. After lymphocyte transfusion, the probability of relapse for patients treated in cytogenetic and hematologic relapse was less than 20%, and for patients treated in transformed phase Abbreviations: CML, chronic myelogenous leukemia; PV, polycythemia vera; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; NA, not applicable.
it was 100% (Fig 1) . Remissions were longer in patients with AML or MDS than in patients with ALL (Fig 2) .
Ten patients had unrelated HLA-identical donors, and 6 of 8 evaluable patients responded to donor lymphocyte transfusions. A patient with Philadelphia-negative CML was treated with lymphocyte transfusions from his monozygotic twin brother without success. Fisher's exact test CMUpolycythemia vera versus AMUMDSIALL:
P < .000001; CML cytogenetidhematologic relapse versus transformed: P = ,0015. AMUMDS versus ALL: P = ,049.
Patients in remission after chemotherapy and patients surviving less than 30 days after transfusion were excluded from evaluation.
Survival and complications of treatment. The probability of survival at 2 years is 67% for patients with CMLPCV. The median survival time is 248 days for patients with AMW MDS and 132 days for patients with ALL (Fig 3) . Sixtyfour patients died after treatment with lymphocyte transfusions, 47 patients with recurrent leukemia, and 17 patients in remission. Six patients died with myelosuppression, 4 with GVHD and 4 with the combination of GVHD and myelosuppression ( Table 4) . The actuarial probability of death in remission at 1 year was: 10% in AMWMDS, 5% in ALL, and 18% in CMLPCV.
GVHD occurred in 79 of 133 patients (59%) requiring treatment in 55 patients (41%). Myelosuppression is a complication of donor lymphocyte transfusion observed in patients not treated with chemotherapy. Myelosuppression was rare in patients with cytogenetic relapse of CML (2 of 15) and in chemotherapy-induced remission ( 2 of 18); it was frequent in hematologic relapse of CML (25 of 50) (P = .Ol). In 5 patients, myelosuppression was corrected by the infusion of donor marrow without prior immune suppression; 30 patients recovered spontaneously.
Pretreatment factors influencing the response. Pretreatment factors related to the transplant center, the patient, its disease, type of the donor, the transplant procedure, the type, and the treatment of relapse were evaluated for their influence on response (Table 5) . Patients with CML/PV and patients with diseases other than CMWPV were analyzed sepa- rately, as the response to donor lymphocyte transfusions was significantly better in CMLffV (P < .OOOOl). In patients with diseases other than CMLffV significance of any pretreatment factor could not be shown.
In CML, the type of relapse was related to the stage of the disease at the time of transplantation: of 17 patients treated for cytogenetic relapse, 16 had received transplants in chronic phase and 1 patient in accelerated phase; of 54 patients treated in hematologic relapse, 44 had received transplants in chronic phase, and 10 had received transplants in accelerated phase; of 14 patients treated for relapse in transformed phase, 8 had received transplants in chronic phase, 3 in accelerated phase, and 3 in blastic phase. Remissions were not achieved in patients who had received transplants in blastic phase.
In univariate analysis, the stage of disease at the time of transplantation, and the type of relapse, transformed versus chronic phase, as defined by cytogenetic or hematologic criteria, had the strongest influence on the response to donor lymphocyte transfusions (Table 5) . Depletion of T cells from the graft and absence of GVHD after bone marrow transplantation were favorable for a response to donor lymphocyte transfusions. The number of lymphocytes transfused and the use of interferon-cY had no influence on the response. In a stepwise logistic regression analysis, the type of relapse and the Occurrence of GVHD after marrow transplantation were the independent prognostic factors.
GVHD, myelosuppression, and their correlation to disease response. GVHD and myelosuppression are the major complications of donor lymphocyte transfusions. Their role in the GVL reaction remains to be defined. Symptoms of GVHD developed in 79 of 133 patients (59%); GVHD of grade I1 or greater developed in 55 patients (41%). GVHD was more frequent in patients with CMLJPV than in patients with other diagnoses, but this difference was not significant after adjustment of other factors ( Table 6 ). The occurrence did not depend on whether the patient had developed GVHD after marrow transplantation or on the number of lymphocytes transfused. Depletion of T cells from the original marrow transplant and treatment with interferon-a before or simultaneously with the lymphocyte transfusions were significant risk factors for the development of GVHD after donor lymphocyte transfusions. An effect of the treatment with interferon-a was observed in patients with diagnoses other than CMLPV; it was absent in patients with CML/ Patients in remission after chemotherapy developed less GVHD after lymphocyte transfusion. This influence was only seen after adjustment for other factors that were significant in the univariate analysis. Myelosuppression was observed in patients with predominant hematopoiesis of host type. Patients with donor type hematopoiesis-patients in chemotherapy-induced remission (2 of 19) and patients with cytogenetic relapse of CML (2 of 15)"were less prone to myelosuppression than patients in hematologic relapse of CML (25 of 50) ( P < .008).
The correlation of response with the development of GVHD and myelosuppression was studied in patients with CML (Table 7) . For diseases other than CML, the number of patients given donor lymphocyte transfusions as sole therapy was too small for evaluation. CML patients with any evidence of GVHD, myelosuppression, or both had a high response rate (42 of 46: 91%). Conversely, the response of 1 N -2 0 patients without any GVHD and myelosuppression was 45% (13 of 29).
DISCUSSION
Therapeutic options for patients with recurrent leukemia after bone marrow transplantation are limited. Second marrow transplants from the same donor may be considered, but the mortality and treatment-related morbidity are high and further recurrences are freq~ent.'~.'~ In CML, treatment with interferon-a may suppress the growth of the Philadelphiapositive clone,2'.22 and prolong ~urvival,'~ but it is not curative. Another possibility is adoptive immunotherapy with donor lymphocytes in patients with established chimerism. Transfusions of lymphocytes from the marrow donor exert a strong graft-versus-leukemia effect in patients with recurrent group of patients with CML in various types of relapse and patients with recurrent PCV, AML, MDS, and ALL. It is unlikely that the results are influenced by selective reporting. Centers were asked to report all sequentially treated patients, and the results were discussed with each center. Reports on patients treated for recurrent myeloma and lymphoma were not of interest for this study. Response rates were not different from those of single centers with larger series. The benefits of adoptive immunotherapy with donor lymphocyte transfusions are greatest in patients with CML in cytogenetic and hematologic relapse. Transfusion of donor lymphocytes could induce remissions in PCV, AML, and MDS, but failed to induce remissions in relapsed ALL. Remissions were durable in patients treated in cytogenetic and hematologic relapse of CML: in responding patients the actuarial probability of relapse 3 years after lymphocyte transfusion is less than 20% (Fig 3) . In AML and MDS, duration of remission was longer, six patients are still in remission between 118 and 855 days. In ALL and advanced stage CML, remissions were short and an effect of donor lymphocyte transfusion on the duration of chemotherapy-induced remissions could not be shown.
In CML, the response to adoptive immunotherapy was influenced favorably by the absence of acute or chronic GVHD after transplantation and the absence of blastic transformation (Table 5 ). Due to recurrent CML, myeloid cells were either a mixture of host and donor-derived cells or host type exclusively.* During the response to adoptive immuno-CML.8-15.24-26 The present study includes a relatively large therapy complete chimerism is reestablished.' Severe myelosuppression may develop in responding patients. Myelosuppression is best explained by a direct effect of the transfused lymphocytes on hematopoietic cells of the host as seen in transfusion-associated GVHD.27 Pancytopenia was rare in patients with cytogenetic relapse of CML and patients in remission after chemotherapy (Table 6 ). In both situations, hematopoiesis is maintained predominantly by donor type cells. In hematologic relapse of CML, most hemopoietic cells come from the leukemia and are of host type. Nevertheless, pancytopenia may not occur if hematopoietic stem cells of donor type are present in sufficient amounts. Evidence for a direct cytotoxic effect and the role of donor type stem cells comes from the infusion of marrow from the donor: infusion of donor marrow did correct myelosuppression in five patients without further immunosuppressive treatment.
Depletion of T cells from the previous marrow graft had a weak influence on the response of recurrent CML to lymphocyte transfusions, but complications of lymphocyte transfusions were increased in all patient groups. Patients with T-cell-depleted grafts developed myelosuppression and GVHD more frequently. In contrast to the results in animal experiments, GVHD occurred in 60% of the patients. In mice2' and donor lymphocytes can be transfused in large amounts without producing GVHD once chimerism and tolerance is established. Risk factors for de novo GVHD after lymphocyte transfusions are depletion of T cells from the previous marrow graft and treatment with interferon-a at the time of lymphocyte transfusions ( Table 6 ). The effect of interferon-a on de novo GVHD was most prominent in patients with AMLA4DS and ALL ( P = .003) and not evident in CMLPCV. Interferon-a can upregulate the expression of class I antigens of the major histocompatibility complex, activate natural killer (NK) cells and induce the secretion of other c y t~k i n e s .~~ Thus, it may stimulate GVHD in the absence of immunosuppressive treatment. In CML, stimulation of GVHD by interferon-a may be less effective, as CML cells often produce proinflammatory cytokines. such as tumor necrosis factor-a (TNF-cx)~' and interleukin-lp (IL-ID)" that stimulate transfused T cells of the donor.
The correlation of de novo GVHD after lymphocyte transfusion with T-cell depletion at marrow transplantation is strong in AML/MDS and CMLPCV ( P = .04) and not evident in ALL. However, the number of patients with ALL and T-cell depletion is small. Recipients of T-cell-depleted marrow grafts may survive despite histoincompatibility and may develop more frequently GVHD and myelosuppression after lymphocyte transfusions. Alternatively, a persisting Tcell deficiency in these patients may fail to maintain tolerance if challenged by transfused lymphocytes.
There is a close association of the GVL effect with either de novo GVHD or myelosuppression or both ( Table 7) , but there is also evidence for a GVL effect separate from myelosuppression and de novo GVHD. The risk factors for these complications differ from the pretreatment factors influencing the response and a GVL effect was observed in 13 of 29 CML-patients (45%) without clinical evidence of GVHD or myelosuppression. In the latter patients, the response may (77) 37 (77) 22 (69) 32 (80) 27 (68) 50 (71) 9 (90) 39 (71) 20 (80) 50 (79) 5 (38) 30 (65) 25 (83) 26 (84) 29 (64) 28 (70) 31 (78) 14 ( result from a reaction against leukemia-specific antigens or from the GVH reaction against minor histocompatibility antigens on leukemic cells. Some minor histocompatibility antigens are predominantly expressed on hematopoietic pro- . Increased serum levels of TNF-(Y after transplantation predict a high probability of GVHD." The absence of LFA-1 on leukemia cells is associated with a lesser sensitivity to lysis by minor histocompatibility antigen-2 specific cytotoxic T lymphocyte~.~~ Interferons are potent stimulators of monocytes and macrophages and inhibit the growth of CML cells by an unknown mechanism.30 It was hoped that treatment with interferon-@ would control the growth of recurrent CML and stimulate the GVL reaction. Unfortunately, treatment with interferon-a did not improve the response significantly, but stimulated GVHD in acute leukemia. It remains unclear why myeloid leukemias respond better to this form of adoptive immunotherapy than lymphoid leukemia. In myeloid leukemias, in particular chronic myeloge- (25) 19 (30) 22 (37) 25 (32) 16 (37) 18 (24) 25 (52) 20 (36) 21 (31) 22 (37) 19 (30) 27 (43) 13 (25) 37 (39) 1 (6) 18 ( nous leukemia, allogeneic antigen-presenting cells are of leukemia origin, and these cells may be particularly able to stimulate and sustain the GVL reaction. A variety of different cells is transfused in the leukocyte concentrates, but only T lymphocytes have sufficient longevity to explain the results. Long-term survival of transfused T cells has been demonstrated with gene marking studies.36 Transfused donor T cells may recognize antigens of the host foreign to the donor and specifically react against leukemia cells of the host, because immunosuppressive treatment is not given for prophylaxis of GVHD. The observed GVL effect in our patients may result from a cytotoxic T-cell response against leukemia-specific antigens or minor antigens. In CML the bcrlabl fusion protein is a candidate for a ieukemia-specific antigen. Proliferative T-cell responses against a peptide of this protein have been described,37 but leukemia-specific cytotoxicity has not been found. The GVL effect may develop within 4 weeks after transfusion, but the 
